Henrik Krook appointed VP Commercial Operations at PledPharma
November 6, 2020
Stockholm, November 6, 2020. PledPharma AB (STO: PLED) today announced that Henrik Krook takes on the position as Vice President Commercial Operations at PledPharma. The appointment is complementing PledPharma’s acquisition of Rare Thyroid Therapeutics (RTT), creating a new focused orphan drug development company with a commercial capability. Henrik will join the company in December.
Henrik has a broad experience from over 15 years in commercial leadership settings, including both big pharma and biotechs. He has direct experience in general management, business development, market access, marketing, sales, clinical trials and strategy formulation, including the orphan drug segment, with a track record of developing companies, organizations and assets to ensure continuous value creation. He has previously held different senior corporate and commercial advisory roles for biotech companies such as Affibody and senior managerial positions at e g Alexion, Novartis and Roche.
He has a PhD in clinical immunology from Uppsala University Hospital and an Executive MBA from Stockholm School of Economics.
“We are very happy to recruit Henrik. With his extensive experience from preparing and executing launches of specialty care drugs, including several in rare diseases, he will be an important addition when we now take important steps towards creating a orphan drug company with products on the market where there is a great unmet medical need. With Henrik on board, we are starting to build the capability to be able to launch our lead candidates Aladote® and Emcitate® in EU and US through a niche commercial organization in approximately three years,” said Nicklas Westerholm, CEO, PledPharma.